AbbVie | ABBV - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 10.77B 4.2B 2026-09
Abbott USD 4.05B 1.05B 2026-09
ALKERMES USD 631.31M 119.78M 2026-09
Amgen USD 13.19B 799M 2026-09
AstraZeneca USD 4.89B 2.67B 2026-06
Biogen USD 1.3B 18.9M 2026-09
BioMarin Pharmaceutical USD 736.01M 138M 2026-09
Bristol-Myers Squibb USD 9.57B 852M 2026-09
Coherus Biosciences USD 82.92M 32.32M 2026-06
Eisai JPY 245.42B 56.22B 2026-03
Eli Lilly USD 4.89B 4.07B 2026-09
Gilead Sciences USD 3.18B 4.45B 2026-06
GlaxoSmithKline GBP 3.1B 337M 2026-06
J&J USD 16.91B 3.51B 2026-09
Medtronic USD 1.69B 258M 2026-06
Merck USD 9.55B 2.7B 2026-09
Neurocrine Biosciences USD 641.5M 309.1M 2026-09
Novartis USD 8.87B 1.25B 2026-09
Pacira USD 1.79B 1.58B 2026-09
Perrigo USD 436.6M 36.9M 2026-09
Pfizer USD 1.82B 848M 2026-09
Regeneron Pharmaceuticals USD 3.66B 1.2B 2026-09
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
UCB EUR 1.57B 1.14B 2024-12
Ultragenyx Pharmaceutical USD 150M 25M 2026-09
United Therapeutics USD 1.19B 614.3M 2026-09
Vertex Pharmaceuticals USD 6.3B 1.55B 2026-09
Zoetis USD 1.33B 143M 2026-09